GSK Investigational Site

Parktown 2193

0 studies enrolling now · 9 studies all time

What they study most

Crohn's Disease, Diabetes Mellitus, Type 2, Irritable Colon, Lung Cancer, Non-Small Cell, Nausea, Nausea and Vomiting, Chemotherapy-Induced, Neoplasms, Breast, Neoplasms, Prostate, Vomiting

Studies at this site

• A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer — Running, not enrolling
• A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease — Completed
• Open-Label Extension Study of GSK1605786A — Stopped early
• GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease — Stopped early
• Thiazolidinedione Intervention With Vitamin D Evaluation — Stopped early
• "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk — Completed
• Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS) — Completed
• Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer — Completed
• Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting — Completed